NASHVILLE, Tenn., Feb. 27,
2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a
global leader in supply chain solutions for cell & gene
therapies, today announced that the Company will report financial
results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets
close.
In addition to the earnings release, a document titled "Cryoport
Fourth Quarter and Full Year 2023 in Review", providing a review of
Cryoport's financial and operational performance and a general
business update, will be issued at 4:05 p.m. ET on Tuesday, March 12, 2024. The document is designed
to be read in advance of the questions and answers conference call
and will be accessible at
https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call the same day at
5:00 p.m. ET. The conference call
will be in the format of a questions and answers session and will
address questions members of the investment community have
regarding the Company's reported results. A slide deck will
accompany the call.
Conference Call Information
Date:
|
Tuesday, March 12,
2024
|
Time:
|
5:00 p.m. ET
|
Dial-in numbers:
|
1-888-886-7786 (U.S.),
1-416-764-8658 (International)
|
Confirmation code:
|
Request the "Cryoport
Call" or Conference ID: 33425097
|
Live webcast:
|
'Investor Relations'
section at www.cryoportinc.com or click here.
|
|
Please allow 10 minutes
prior to the call to visit this site to download and install any
necessary audio software.
|
The questions and answers call will be recorded and available
approximately three hours after completion of the live event in the
Investor Relations section of the Company's website at
www.cryoportinc.com for a limited time. To access the replay
of the questions and answers click here. A dial-in replay of the
call will also be available to those interested, until March 19, 2024. To access the replay, dial
1-844-512-2921 (United States) or
1-412-317-6671 (International) and enter replay entry code:
33425097#.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply
chain solutions for cell & gene therapies that enable
manufacturers, contract manufacturers (CDMO's), contract research
organizations (CRO's), developers, and researchers to carry out
their respective business with certainty.
We provide a broad array of supply chain solutions for the
life sciences industry. Through our platform of critical
products and solutions including advanced temperature-controlled
packaging, informatics, specialized bio-logistics services,
bio-storage, bio-services, and cryogenic systems, we are
"Enabling the Future of Medicine", worldwide, through our
innovative systems, compliant procedures, and agile approach to
superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complimented by 50
global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Portugal,
Germany, Australia, India, and China.
For more information, visit www.cryoportinc. com or follow us on
LinkedIn at https://www.linkedin.com/company/cryoportinc or
@cryoport on X, formerly known as Twitter at
www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this
press release which are not purely historical, including statements
regarding the Company's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to the
Company's industry, business, long-term growth prospects, including
expected growth in all of the Company's markets, plans, strategies,
acquisitions, future financial results and financial condition,
such as the Company's outlook and guidance for full year 2023
revenue and the related assumptions and factors expected to drive
revenue, projected growth trends in the markets in which the
Company operates, the Company's plans and expectations regarding
the launch of new products and services, such as the expected
timing and benefits of such products and services launches, the
Company's plans to further strengthen its business and continue to
position itself for long-term and profitable growth in the cell and
gene therapy industry, and anticipated regulatory filings or
approvals with respect to the products of the Company's clients. It
is important to note that the Company's actual results could differ
materially from those in any such forward-looking statements.
Factors that could cause actual results to differ materially
include, but are not limited to, risks and uncertainties associated
with the effect of changing economic and geopolitical conditions,
including supply chain constraints, inflationary pressures, the
effects of foreign currency fluctuations, trends in the products
markets, variations in the Company's cash flow, market acceptance
risks, and technical development risks. The Company's business
could be affected by a number of other factors discussed in the
Company's SEC reports, including in the "Risk Factors" section of
its most recently filed periodic reports on Form 10-K and Form
10-Q, as well as in its subsequent filings with the SEC. The
forward-looking statements contained in this press release speak
only as of the date hereof and the Company cautions investors not
to place undue reliance on these forward-looking statements. Except
as required by law, the Company disclaims any obligation, and does
not undertake to update or revise any forward-looking statements in
this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-12-2024-302072322.html
SOURCE Cryoport, Inc.